Liver cirrhosis is a chronic liver disease characterized by permanent scarring that replaces healthy tissue and progressively impairs liver function. As fibrosis advances, patients can develop portal hypertension, decompensation, and eventual liver failure.
A study from the University of Osaka identified the integrin αV–YAP–CTGF pathway linking chronic liver congestion to fibrosis. The findings point to a potential therapeutic target in congestion-related liver disease.
A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598669 |
Austrian PBC Registry |
RECRUITING | |
| NCT07590284 |
Sonazoid CEUS for Early HCC Surveillance |
NOT_YET_RECRUITING | NA |
| NCT07587671 |
Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis |
NOT_YET_RECRUITING | NA |
| NCT07585890 |
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe |
RECRUITING | |
| NCT07571876 |
Ultrasound Prediction of Esophageal Variceal Bleeding Risk |
NOT_YET_RECRUITING | |
| NCT07571460 |
Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis |
COMPLETED | PHASE4 |
| NCT07561138 |
Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation |
RECRUITING | NA |
| NCT07560202 |
Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors |
ACTIVE_NOT_RECRUITING | |
| NCT07553858 |
Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy |
NOT_YET_RECRUITING | NA |
| NCT07529262 |
Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial |
NOT_YET_RECRUITING | PHASE3 |
